Urinary Tract Infection Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs), By Indication (Complicated UTI, Uncomplicated UTI, and Other Indications), and By Region, Competition 2018-2028

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

 

Forecast Period

2024-2028

Market Size (2022)

USD 7.20 billion

CAGR (2024-2028)

3.12%

Fastest Growing Segment

Penicillin and Combinations

Largest Market

North America

 

Market Overview

Global Urinary Tract Infection Therapeutics Market has valued at USD 7.20 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 3.12% through 2028. Urinary tract infection (UTI) therapeutics refers to the medical treatments and interventions used to manage and treat infections in the urinary tract. UTIs are bacterial infections that can affect various parts of the urinary system, including the bladder, urethra, ureters, and kidneys. UTI therapeutics are designed to alleviate symptoms, eliminate infecting bacteria, and prevent complications. Antibiotics are the most common and effective treatment for bacterial UTIs. They work by targeting and killing the bacteria causing the infection. The choice of antibiotic depends on factors such as the type of bacteria, antibiotic susceptibility, and patient-specific considerations. Empiric therapy involves prescribing antibiotics based on common bacterial pathogens and resistance patterns in the patient's community. This approach provides rapid treatment while waiting for specific laboratory test results.

UTIs are one of the most common bacterial infections, affecting millions of individuals worldwide. The high incidence of UTIs drives demand for effective treatment options. The aging population is more susceptible to UTIs due to weakened immune systems and other health conditions. As the global population ages, the prevalence of UTIs is likely to increase, contributing to market growth. Improved access to healthcare services, especially in developing regions, allows for earlier diagnosis and treatment of UTIs, which can boost the demand for UTI therapeutics. Rising antibiotic resistance is a significant concern in healthcare. As bacterial resistance to commonly used antibiotics increases, there's a need for innovative therapeutics to combat resistant strains. Improved diagnostic methods, including rapid point-of-care tests and advanced imaging techniques, enable more accurate and timely diagnosis of UTIs, leading to appropriate treatment.

Key Market Drivers

Advancements in Diagnostics

 Advancements in diagnostics for urinary tract infections (UTIs) have the potential to improve patient outcomes by enabling more accurate and timely diagnosis, leading to appropriate and targeted treatment. Rapid diagnostic tests that can be performed at the point of care, such as in a doctor's office or a clinic, are being developed. These tests aim to provide quick results, allowing healthcare providers to make treatment decisions without waiting for laboratory results. Techniques like polymerase chain reaction (PCR) and nucleic acid amplification assays can identify the genetic material of bacteria causing the infection. These methods offer high sensitivity and specificity, enabling the detection of even low bacterial loads. Researchers are exploring the use of specific biomarkers in urine or blood to detect UTIs. These biomarkers could help differentiate between bacterial and non-bacterial causes of symptoms and guide treatment decisions. Smartphone apps and devices with integrated diagnostic capabilities are being developed. These tools might allow users to conduct simple urine tests at home and receive immediate results.

Microfluidic platforms are being developed to automate and miniaturize diagnostic processes. These devices can analyze urine samples for the presence of bacteria and biomarkers quickly and efficiently. Mass spectrometry-based techniques are being explored for identifying bacterial pathogens and detecting antimicrobial resistance. These methods can provide detailed information about the infecting organisms. Advances in culture techniques, such as automated systems, can speed up the identification of bacterial species causing UTIs and provide information about antibiotic susceptibility. Imaging techniques like ultrasound and computed tomography (CT) scans can help visualize the urinary tract and identify structural abnormalities that might contribute to recurrent UTIs. Endoscopic procedures that allow visualization of the urinary tract can help identify anatomical abnormalities, stones, or other factors contributing to UTIs. Artificial intelligence and machine learning algorithms can analyze large datasets to identify patterns and predict UTI outcomes based on patient history, symptoms, and test results. Metabolomics involves analyzing the metabolites present in urine samples. This approach can provide insights into the host-microbe interaction during UTIs and potentially lead to new diagnostic markers. Researchers are exploring non-invasive methods for UTI diagnosis, such as analyzing urine odor or using sensor-based technologies to detect bacterial presence. This factor will help in the development of Global Urinary Tract Infection Therapeutics Market.

Growing Aging Population

Aging is associated with a decline in the immune system's function, making older adults more susceptible to infections, including UTIs. A weakened immune response can result in a higher incidence of infections and a greater need for appropriate treatment. Older individuals often have underlying health conditions such as diabetes, kidney disease, and urinary incontinence. These conditions can increase the risk of UTIs and make them more challenging to manage, requiring specialized therapeutics. Anatomical changes in the urinary tract, including weakened bladder muscles and reduced bladder capacity, can contribute to UTIs in older adults. These changes may necessitate tailored treatment approaches. Older adults may have a higher likelihood of requiring urinary catheters, which increases the risk of catheter associated UTIs. Effective therapeutics are crucial to managing and preventing these infections. Older adults may be more susceptible to UTIs during hospital stays or in long-term care settings. Effective treatments are essential to prevent complications and improve patient outcomes.

The use of multiple medications (polypharmacy) is common in the elderly. Certain medications may increase the risk of UTIs or interact with antibiotics, requiring careful consideration of therapeutics. Older adults often require specialized prevention and management strategies for UTIs. Effective therapeutics play a crucial role in preventing recurrent infections and associated complications. UTIs can significantly impact the quality of life for older adults, leading to discomfort, pain, and functional limitations. Access to effective therapeutics is essential to alleviate symptoms and improve well-being. The aging population tends to have higher healthcare utilization rates. This increased demand for medical services includes diagnosis, treatment, and management of UTIs, contributing to the demand for therapeutics. As people live longer, they have a higher cumulative risk of experiencing UTIs over their lifetimes. The sustained demand for UTI therapeutics is driven by the ongoing healthcare needs of the aging population. This factor will pace up the demand of Global Urinary Tract Infection Therapeutics Market.

Increasing Antibiotic Resistance Concerns

Antibiotic resistance occurs when bacteria evolve to resist the effects of antibiotics, rendering traditional treatments ineffective. As antibiotic resistance increases, the range of effective antibiotics for treating UTIs becomes narrower, emphasizing the need for new and alternative therapeutic options. UTIs that are caused by antibiotic-resistant bacteria are harder to treat with conventional antibiotics. This can lead to treatment failures, prolonged infections, and a higher risk of complications. Antibiotic-resistant UTIs are more likely to recur, as bacteria that survive antibiotic treatment can lead to relapses. Effective UTI therapeutics are vital to prevent recurrent infections and break the cycle of resistance. In healthcare settings, patients with antibiotic resistant UTIs can experience longer hospital stays, increased healthcare costs, and a higher risk of adverse outcomes. Effective therapeutics are crucial to managing and preventing these infections. Resistant bacteria can spread within communities, increasing the risk of acquiring antibiotic resistant UTIs. This spread highlights the urgency of developing and using effective therapies to curb the proliferation of resistance.

Antibiotic resistance is a global public health concern. Infections that were once easily treatable may become life-threatening due to the lack of effective antibiotics. Developing new UTI therapeutics is part of the broader effort to combat antibiotic resistance. The increased healthcare costs associated with treating antibiotic-resistant infections, including UTIs, can strain healthcare systems and burden both patients and societies. Effective therapeutics can help mitigate these economic challenges. Governments, healthcare organizations, and international bodies are focusing on addressing antibiotic resistance through awareness campaigns, surveillance programs, and research efforts. These initiatives underscore the importance of developing effective UTI therapeutics. The urgency of antibiotic resistance has spurred research into new drug classes, alternative treatments, and combination therapies. Pharmaceutical companies are investing in the development of innovative therapeutics to combat resistant UTIs. Healthcare providers are increasingly practicing antibiotic stewardship to promote responsible antibiotic use. Developing effective UTI therapeutics that are less likely to contribute to resistance aligns with these stewardship principles. The complexity of antibiotic resistance patterns calls for personalized treatment strategies. Effective UTI therapeutics need to address specific bacterial strains and resistance mechanisms. This factor will accelerate the demand of Global Urinary Tract Infection Therapeutics Market


Download Free Sample Report

Key Market Challenges

Emergence of Virulent Strains

Virulent strains of bacteria can exhibit higher levels of resistance to antibiotics, rendering conventional treatments less effective. This can lead to prolonged infections, increased healthcare utilization, and a higher risk of complications. Virulent strains often cause more severe infections with more pronounced symptoms. Patients infected with such strains may experience more discomfort and require more aggressive treatment strategies. UTIs caused by virulent strains can be associated with a higher risk of complications, including kidney infections (pyelonephritis) and bloodstream infections (bacteremia), which can be life-threatening if not promptly treated. Hospitals and healthcare settings can be reservoirs for virulent bacterial strains. UTIs acquired in healthcare settings often involve more resistant and virulent strains, necessitating specialized therapeutics and infection control measures. The emergence of drug-resistant and virulent strains can limit the available treatment options for UTIs. Healthcare providers may need to rely on more powerful antibiotics, combination therapies, or alternative treatment approaches. Treating infections caused by virulent strains can lead to longer hospital stays, increased healthcare costs, and the need for more intensive interventions. This places a burden on healthcare systems and patients alike. The emergence of new virulent strains underscores the need for ongoing antibiotic development. However, the process of developing and bringing new antibiotics to market can be complex and time-consuming.

Limited New Drug Development

The rise of antibiotic-resistant bacteria is a pressing concern. Limited new drug development contributes to a shortage of effective antibiotics against resistant strains, making it difficult to treat certain UTIs. The absence of new drugs can lead to treatment failures, prolonged infections, and recurrent UTIs. This can result in patient discomfort, increased healthcare utilization, and higher costs. With few new drugs entering the market, healthcare providers may have limited options to choose from. This could lead to over-reliance on a small set of antibiotics, potentially exacerbating resistance issues. The lack of new drug development can lead to economic consequences, including increased healthcare costs due to extended treatment periods and hospitalizations for severe cases. A lack of innovation hinders the discovery of novel treatment approaches, leaving patients with fewer alternatives to traditional antibiotics. The aging population and increased healthcare demand mean that UTI treatment requirements are on the rise. New drugs are crucial to meet this growing demand. Limited potential for profit from developing new UTI drugs might discourage pharmaceutical companies from investing in research and development efforts. UTIs can be caused by various bacterial species. Developing drugs that target a wide range of pathogens requires substantial research and resources.

Key Market Trends

Antibiotic Stewardship

Antibiotic stewardship refers to the coordinated efforts to promote the responsible and judicious use of antibiotics to prevent the development of antibiotic resistance, improve patient outcomes, and optimize healthcare resources. Antibiotic stewardship programs aim to ensure that antibiotics are prescribed only when necessary and appropriate. This approach helps prevent the overuse and misuse of antibiotics, preserving their effectiveness for future use. One of the primary goals of antibiotic stewardship is to combat the development of antibiotic resistance. By limiting unnecessary antibiotic use, the emergence and spread of resistant bacteria can be slowed down. Antibiotic stewardship encourages healthcare providers to explore alternative treatment options, such as non-antibiotic therapies, for managing UTIs when appropriate. Stewardship practices emphasize individualized treatment plans based on the patient's condition, the causative pathogen, and antibiotic susceptibility. This approach improves treatment outcomes and minimizes unnecessary exposure to antibiotics. Antibiotic stewardship programs involve educating healthcare professionals, patients, and the public about the importance of proper antibiotic use, the risks of resistance, and the benefits of responsible prescribing. Stewardship aligns with evidence-based guidelines for UTI treatment, ensuring that antibiotics are prescribed according to established best practices. Electronic health record systems and clinical decision support tools can assist healthcare providers in selecting appropriate antibiotics based on patient-specific factors and local resistance patterns.

Segmental Insights

Indication Insights

In 2022, the Global Urinary Tract Infection Therapeutics Market dominated by complicated UTI segment in the forecast period and is predicted to continue expanding over the coming years. Complicated UTIs are infections that occur in individuals with anatomical or functional abnormalities of the urinary tract, underlying health conditions, or compromised immune systems. These infections tend to be more severe and challenging to treat. Therefore, healthcare providers may rely on more potent or specialized therapies, contributing to the dominance of this segment. The complexity of complicated UTIs might necessitate the use of specialized or combination therapies to effectively treat the infection. This requirement for tailored treatments could result in a higher demand for specific therapeutic options. As the population ages and chronic health conditions become more prevalent, the incidence of complicated UTIs could increase. This demographic shift might contribute to the dominance of this segment.

Drug Insights

In 2022, the Global Urinary Tract Infection Therapeutics Market dominated by quinolones drugs segment and is predicted to continue expanding over the coming years.  Quinolones are broad-spectrum antibiotics, which means they are effective against a wide range of bacteria. UTIs can be caused by various bacterial strains, and quinolones' ability to target a broad spectrum of bacteria makes them versatile in treating different types of UTIs. Many quinolone antibiotics can be administered orally, making them convenient for both healthcare providers and patients. This ease of administration can contribute to their popularity in the treatment of UTIs. Quinolones often have a relatively fast onset of action, leading to quick symptom relief for patients suffering from UTIs. Healthcare providers often have experience with prescribing quinolones, as they have been used for treating a variety of infections for decades. This familiarity can lead to their continued use in UTI treatment.



Download Free Sample Report

Regional Insights

The North America region dominates the Global Urinary Tract Infection Therapeutics Market in 2022. The region boasts well-developed healthcare infrastructure, including hospitals, clinics, research institutions, and pharmaceutical companies. This infrastructure facilitates the research, development, and distribution of UTI therapeutics. North America is home to several major pharmaceutical companies and biotechnology firms that invest heavily in research and development. This industry's innovation contributes to the availability of effective UTI therapeutics. The United States and Canada have a strong research culture, with numerous clinical trials and research studies conducted to improve medical treatments. This environment can lead to the discovery of new and improved UTI therapeutics.

Recent Developments

  • In September 2021, Biapenem was launched and made available to patients with intra-abdominal infections, lower respiratory infections, or difficult urinary tract infections, according to BDR Pharma, one of India's top generic pharmaceutical businesses. With the release of biapenem under the trade name Biapen on the market, BDR Pharma raises the bar for its extensive line of critical care segment medicines. The first company to recognize and develop this product was BDR Pharma, which also co-sponsored clinical trials with some of the industry's top competitors in the critical care market. Additionally, BDR Pharma was the first to receive this medication's DCGI (Drug Controller General of India) approval. Patients with serious urinary tract infections, intraabdominal infections, or lower respiratory infections typically receive biapenem prescriptions. It belongs to a class of essential parenteral carbapenem antibiotic. Biapen's dosage is considerably lower than that of the current generation of carbapenems, nevertheless.
  • In October 2021, The U.S. Food and Drug Administration (FDA) has received a new drug application (NDA) for tebipenem HBr tablets to treat complicated urinary tract infections (cUTI), including pyelonephritis. Spero Therapeutics Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercialising treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, Tebipenem HBr would be the only oral carbapenem antibiotic offered for use in cUTI if it were authorised.

Key Market Players

  • AstraZeneca PLC.
  • Bayer AG
  • Cipla Inc.
  • GlaxoSmithKline PLC
  • Shionogi & Co. Ltd
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co. Inc
  • Bristol-Myers Squibb Company
  • Almirall SA
  • Allergan Inc.

By Drug

By Indication

By Region
  • Penicillin and Combinations
  • Quinolones
  • Cephalosporin
  • Azoles and Amphotericin B
  • Nitrofurans
  • Other Drugs
  • Complicated UTI
  • Uncomplicated UTI
  • Other Indications
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • South America

Report Scope:

In this report, the Global Urinary Tract Infection Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Urinary Tract Infection Therapeutics Market, By Drug:

o    Penicillin and Combinations

o    Quinolones

o    Cephalosporin

o    Azoles and Amphotericin B

o    Nitrofurans

o    Other Drugs

  • Urinary Tract Infection Therapeutics Market, By Indication:

o    Complicated UTI

o    Uncomplicated UTI

o    Other Indications

  • Global Urinary Tract Infection Therapeutics Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Urinary Tract Infection Therapeutics Market.

Available Customizations:

Global Urinary Tract Infection Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Urinary Tract Infection Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.   Markets Covered

1.2.2.   Years Considered for Study

1.2.3.   Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Impact of COVID-19 on Global Urinary Tract Infection Therapeutics Market

5.    Voice of Customer

6.    Global Urinary Tract Infection Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs)

6.2.2.     By Indication (Complicated UTI, Uncomplicated UTI, and Other Indications)

6.2.3.     By Region

6.2.4.     By Company (2022)

6.3.  Market Map

7.    Asia Pacific Urinary Tract Infection Therapeutics Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Drug

7.2.2.     By Indication

7.2.3.     By Country

7.3.  Asia Pacific: Country Analysis

7.3.1.     China Urinary Tract Infection Therapeutics Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Drug

7.3.1.2.2.             By Indication

7.3.2.     India Urinary Tract Infection Therapeutics Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Drug

7.3.2.2.2.             By Indication

7.3.3.     Australia Urinary Tract Infection Therapeutics Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Drug

7.3.3.2.2.             By Indication

7.3.4.     Japan Urinary Tract Infection Therapeutics Market Outlook

7.3.4.1.         Market Size & Forecast

7.3.4.1.1.             By Value

7.3.4.2.         Market Share & Forecast

7.3.4.2.1.             By Drug

7.3.4.2.2.             By Indication

7.3.5.     South Korea Urinary Tract Infection Therapeutics Market Outlook

7.3.5.1.         Market Size & Forecast

7.3.5.1.1.             By Value

7.3.5.2.         Market Share & Forecast

7.3.5.2.1.             By Drug

7.3.5.2.2.             By Indication

8.    Europe Urinary Tract Infection Therapeutics Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Drug

8.2.2.     By Indication

8.2.3.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Urinary Tract Infection Therapeutics Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Drug

8.3.1.2.2.             By Indication

8.3.2.     Germany Urinary Tract Infection Therapeutics Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Drug

8.3.2.2.2.             By Indication

8.3.3.     Spain Urinary Tract Infection Therapeutics Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Drug

8.3.3.2.2.             By Indication

8.3.4.     Italy Urinary Tract Infection Therapeutics Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Drug

8.3.4.2.2.             By Indication

8.3.5.     United Kingdom Urinary Tract Infection Therapeutics Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Drug

8.3.5.2.2.             By Indication

9.    North America Urinary Tract Infection Therapeutics Market Outlook

9.1.  Market Size & Forecast

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Drug

9.2.2.     By Indication

9.2.3.     By Country

9.3.  North America: Country Analysis

9.3.1.     United States Urinary Tract Infection Therapeutics Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Drug

9.3.1.2.2.             By Indication

9.3.2.     Mexico Urinary Tract Infection Therapeutics Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Drug

9.3.2.2.2.             By Indication

9.3.3.     Canada Urinary Tract Infection Therapeutics Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Drug

9.3.3.2.2.             By Indication

10.  South America Urinary Tract Infection Therapeutics Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Drug

10.2.2.  By Indication

10.2.3.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Urinary Tract Infection Therapeutics Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Drug

10.3.1.2.2.           By Indication

10.3.2.  Argentina Urinary Tract Infection Therapeutics Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Drug

10.3.2.2.2.           By Indication

10.3.3.  Colombia Urinary Tract Infection Therapeutics Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Drug

10.3.3.2.2.           By Indication

11.  Middle East and Africa Urinary Tract Infection Therapeutics Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Drug

11.2.2.  By Indication

11.2.3.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Urinary Tract Infection Therapeutics Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Drug

11.3.1.2.2.           By Indication

11.3.2.  Saudi Arabia Urinary Tract Infection Therapeutics Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Drug

11.3.2.2.2.           By Indication

11.3.3.  UAE Urinary Tract Infection Therapeutics Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Drug

11.3.3.2.2.           By Indication

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

13.1.              Recent Developments

13.2.              Product Launches

13.3.              Mergers & Acquisitions

14.  Global Urinary Tract Infection Therapeutics Market: SWOT Analysis

15.  Porter’s Five Forces Analysis

15.1.              Competition in the Industry

15.2.              Potential of New Entrants

15.3.              Power of Suppliers

15.4.              Power of Customers

15.5.              Threat of Substitute Product

16.  PESTLE Analysis

17.  Competitive Landscape

17.1.              Business Overview

17.2.              Company Snapshot

17.3.              Products & Services

17.4.              Financials (In case of listed companies)

17.5.              Recent Developments

17.6.              SWOT Analysis

17.6.1.  AstraZeneca PLC.

17.6.2.  Bayer AG

17.6.3.  Cipla Inc.

17.6.4.  GlaxoSmithKline PLC

17.6.5.  Shionogi & Co. Ltd

17.6.6.  Novartis AG

17.6.7.  Pfizer Inc.

17.6.8.  Merck & Co. Inc

17.6.9.  Bristol-Myers Squibb Company

17.6.10.                Almirall SA

17.6.11.                Allergan Inc.

18.  Strategic Recommendations

19. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Urinary Tract Infection Therapeutics Market was estimated to be USD 7.20 billion in 2022.

down-arrow

Bristol-Myers Squibb Company, Almirall SA, Allergan Inc. are some of the key players operating in the Global Urinary Tract Infection Therapeutics Market.

down-arrow

Access to healthcare varies globally. Inadequate healthcare infrastructure and limited access to medical facilities can hinder timely diagnosis and treatment of UTIs, exacerbating the impact of the condition.

down-arrow

Due to concerns about antibiotic resistance, there has been a growing emphasis on antibiotic stewardship programs.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Global Urinary Tract Infection Therapeutics Market to grow with a CAGR of 3.12%.

Sep, 2023

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Urinary Tract Infection Therapeutics Market.

Why Choose Us